title: Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
abstract: For decades, hundreds of different human tumor type-specific cell lines have been used in experimental cancer research as models for their respective tumors. The veracity of experimental results for a specific tumor type relies on the correct derivation of the cell line. In a worldwide effort, we verified the authenticity of all available esophageal adenocarcinoma (EAC) cell lines. We proved that the frequently used cell lines SEG-1 and BIC-1 and the SK-GT-5 cell line are in fact cell lines from other tumor types. Experimental results based on these contaminated cell lines have led to ongoing clinical trials recruiting EAC patients, to more than 100 scientific publications, and to at least three National Institutes of Health cancer research grants and 11 US patents, which emphasizes the importance of our findings. Widespread use of contaminated cell lines threatens the development of treatment strategies for EAC.
authors.affiliation: Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
authors.forename: Jurjen J
authors.initials: JJ
authors.lastname: Boonstra
authors.forename: Ronald
authors.initials: R
authors.lastname: van Marion
authors.forename: David G
authors.initials: DG
authors.lastname: Beer
authors.forename: Lin
authors.initials: L
authors.lastname: Lin
authors.forename: Paula
authors.initials: P
authors.lastname: Chaves
authors.forename: Catarina
authors.initials: C
authors.lastname: Ribeiro
authors.forename: A Dias
authors.initials: AD
authors.lastname: Pereira
authors.forename: Lúcia
authors.initials: L
authors.lastname: Roque
authors.forename: S Jane
authors.initials: SJ
authors.lastname: Darnton
authors.forename: Nasser K
authors.initials: NK
authors.lastname: Altorki
authors.forename: David S
authors.initials: DS
authors.lastname: Schrump
authors.forename: David S
authors.initials: DS
authors.lastname: Klimstra
authors.forename: Laura H
authors.initials: LH
authors.lastname: Tang
authors.forename: James R
authors.initials: JR
authors.lastname: Eshleman
authors.forename: Hector
authors.initials: H
authors.lastname: Alvarez
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Shimada
authors.forename: Herman
authors.initials: H
authors.lastname: van Dekken
authors.forename: Hugo W
authors.initials: HW
authors.lastname: Tilanus
authors.forename: Winand N M
authors.initials: WN
authors.lastname: Dinjens
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001557:Benzenesulfonates / Q000494:pharmacology; D035843:Biomedical Research / Q000592:standards; D002277:Carcinoma / Q000235:genetics / Q000473:pathology; D018287:Carcinoma, Large Cell / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic / Q000592:standards*; D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology; D016172:DNA Fingerprinting; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology; D009316:National Institutes of Health (U.S.); D009536:Niacinamide / Q000031:analogs & derivatives; D009841:Oligonucleotides; D009842:Oligopeptides / Q000494:pharmacology; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D000077157:Sorafenib; D013274:Stomach Neoplasms / Q000235:genetics / Q000473:pathology; D020080:Tandem Repeat Sequences; D019098:Telomerase / Q000037:antagonists & inhibitors; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; C505952:GRN163L peptide; D009841:Oligonucleotides; D009842:Oligopeptides; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D019098:Telomerase